1609637-56-0

Basic information

• Product Name: (±)-4-(3-fluorophenyl)-3,4-dihydro-1-methyl-5-phenylpyrimidine-2(1H)-thione
• Synonyms: (±)-4-(3-fluorophenyl)-3,4-dihydro-1-methyl-5-phenylpyrimidine-2(1H)-thione
• CAS NO: 1609637-56-0
• Molecular Weight: 298.384
• Mol File: 1609637-56-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (±)-4-(3-fluorophenyl)-3,4-dihydro-1-methyl-5-phenylpyrimidine-2(1H)-thione(CAS DataBase Reference)
• NIST Chemistry Reference: (±)-4-(3-fluorophenyl)-3,4-dihydro-1-methyl-5-phenylpyrimidine-2(1H)-thione(1609637-56-0)
• EPA Substance Registry System: (±)-4-(3-fluorophenyl)-3,4-dihydro-1-methyl-5-phenylpyrimidine-2(1H)-thione(1609637-56-0)

Safety Data

• Hazardous Substances Data: 1609637-56-0(Hazardous Substances Data)

Upstream product

• 1073-06-9 3-fluorobromobenzene 
• 7089-34-1 ((Z)-3-Dimethylamino-2-phenyl-allylidene)-dimethyl-ammonium; perchlorate 
• 103-82-2 phenylacetic acid 
• 1609637-35-5 1-methyl-5-phenylpyrimidine-2(1H)-thione 
• 107337-71-3 3-fluorophenyllithium 

Relevant articles and documents

Regioselective synthesis of novel 4,5-diaryl functionalized 3,4-dihydropyrimidine-2(1H)-thiones via a non-Biginelli-type approach and evaluation of their in vitro anticancer activity

An easy and novel approach to synthesize 4,5-diaryl functionalized 3,4-dihydropyrimidine-2(1H)-thiones via addition of aryllithiums to 5-aryl substituted pyrimidine-2(1H)-thiones, which could be regarded as a method complementary to the most widely used Biginelli-type synthesis, is described. In the reaction of aryllithiums with N-(Me)Bn substituted pyrimidine-2(1H)-thiones a high degree of regioselectivity of addition, leading to 4-aryl adducts, was achieved. Selected compounds tested for their in vitro anticancer activity against four human cancer cell lines showed the greatest activity against breast cancer (MCF7). 1-Benzyl-4-(3-hydroxyphenyl)-5-phenyl substituted 3,4-dihydropyrimidine-2(1H)-thione (10g) exhibiting 10-fold more potent activity than the best known monastrol (MON) stands as a promising candidate for further scaffold and asymmetric synthesis. the Partner Organisations 2014.